TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06292780: A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 220 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$931,260

Rescue Site Savings

+$620,840

Unlock Full NCT06292780 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06292780 Rescue Dossier →